Adderall News and Research RSS Feed - Adderall News and Research

Adderall (dextroamphetamine-amphetamine) is a combination of two synthetic agents with central nervous system stimulant activity. Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation. These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur.
Viewpoints: Wheaton injunction muddies court's ruling on contraceptives; Boston hospital merger problems; advice for new VA chief

Viewpoints: Wheaton injunction muddies court's ruling on contraceptives; Boston hospital merger problems; advice for new VA chief

In a bizarre attempt to have it both ways, the Supreme Court held that a small evangelical Protestant college in Illinois did not have to include contraceptive coverage in employee health insurance even though it didn't fill out the paperwork the government required for claiming an exemption. .. [More]
10,000 toddlers receive medication for ADHD, shows report

10,000 toddlers receive medication for ADHD, shows report

"It does not surprise me that some children are being given medicine as the easy way out but that doesn't mean it's the right way to do it," says Max Wiznitzer, MD, a pediatric neurologist at University Hospitals Rainbow Babies & Children's Hospitals about the Center for Disease Control's estimate 10,000 toddlers receive medication for attention-deficit/hyperactivity disorder (ADHD). [More]
Shire intends to submit NDA for lifitegrast to treat dry eye disease

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work. [More]
Research findings point to potential biomarkers for early detection of at-risk youth

Research findings point to potential biomarkers for early detection of at-risk youth

Researchers at the University of California, San Diego School of Medicine have discovered impaired neuronal activity in the parts of the brain associated with anticipatory functioning among occasional 18- to 24-year-old users of stimulant drugs, such as cocaine, amphetamines and prescription drugs such as Adderall. [More]
Research roundup: Medicaid eligibility; tracking discontinued randomized trials; decline in work-based insurance

Research roundup: Medicaid eligibility; tracking discontinued randomized trials; decline in work-based insurance

Under the Affordable Care Act (ACA), changes in income and family circumstances are likely to produce frequent transitions in eligibility for Medicaid and health insurance Marketplace coverage for low- and middle-income adults. [More]
Viewpoints: 'Middlling news' on enrollment; 'secret mandate exemption;' Obama's surprising appearance between two ferns

Viewpoints: 'Middlling news' on enrollment; 'secret mandate exemption;' Obama's surprising appearance between two ferns

By the beginning of the month, 4.2 million people had selected a plan. But that doesn't mean they have insurance. Reporters on a conference call asked about the number who had paid, and the administration's representatives said they don't know. [More]
Global initiatives underscore shire's long-term commitment to rare disease community

Global initiatives underscore shire's long-term commitment to rare disease community

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced its support of Rare Disease Day and invites others to join them in its continued commitment to the rare disease community. [More]

Impax Laboratories records adjusted net loss of $1.6 million in fourth quarter 2013

Impax Laboratories, Inc. today reported fourth quarter and full year ended December 31, 2013 results. [More]

Shire signs agreement to supply authorized generic version of Adderall XR

Shire plc, announces that its subsidiary Shire US Inc. has entered into an agreement to supply an authorized generic version of its product Adderall XR. [More]
State highlights: Calif. Gov. Vetoes 'biosimilars' bill; health data gateway opens in Calif.; L.A. health workers required to get flu shots

State highlights: Calif. Gov. Vetoes 'biosimilars' bill; health data gateway opens in Calif.; L.A. health workers required to get flu shots

A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs. [More]
First Edition: October 16, 2013

First Edition: October 16, 2013

Today's headlines including stories detailing how certain health law provisions are factoring in to the continuing congressional budget stalemate. [More]

Shire resolves patent infringement lawsuit against Teva relating to INTUNIV tablet

Shire LLC has settled its litigation against Teva Pharmaceuticals USA Inc. ("Teva") in connection with Teva's Abbreviated New Drug Application ("ANDA") for a generic version of Shire's INTUNIV (guanfacince) Extended Release Tablets for the treatment of Attention Deficit Hyperactivity Disorder. [More]
New U-M poll shows 1 in 100 parents believe their kids use prescription stimulants to boost grades

New U-M poll shows 1 in 100 parents believe their kids use prescription stimulants to boost grades

As high schoolers prepare for final exams, teens nationwide may be tempted to use a "study drug" -- a prescription stimulant or amphetamine -- to gain an academic edge. But a new University of Michigan poll shows only one in 100 parents of teens 13-17 years old believes that their teen has used a study drug. [More]
Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22. [More]
Roundup: Battles in five states become central to abortion fight; Calif. prison spending on anti-psychotics raises treatment questions

Roundup: Battles in five states become central to abortion fight; Calif. prison spending on anti-psychotics raises treatment questions

Five states have moved to adopt tighter abortion regulations, including North Dakota, where a new law prohibits abortions as soon as a fetal heartbeat is detected. Jeffrey Brown gets perspectives from Charmaine Yoest of Americans United for Life and Ilyse Hogue of NARAL Pro-Choice America (4/30). [More]
1 in 4 teens misused or abused a prescription drug at least once in their lifetime

1 in 4 teens misused or abused a prescription drug at least once in their lifetime

New, nationally projectable survey results released today by The Partnership at Drugfree.org and MetLife Foundation confirmed that one in four teens has misused or abused a prescription (Rx) drug at least once in their lifetime - a 33 percent increase over the past five years. [More]
FDA approves Teva’s generic Adderall XR ANDA for treatment of ADHD

FDA approves Teva’s generic Adderall XR ANDA for treatment of ADHD

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for the generic version of Shire's Adderall XR Capsules, 5mg, 10mg, 15mg, 20mg, 25mg and 30 mg capsules for the treatment of attention deficit hyperactivity disorder. [More]

Shire, Impax resolve pending generic Adderall XR litigation

Impax Laboratories, Inc. today announced that it has settled all pending litigation with Shire LLC and Shire Laboratories, Inc. relating to supply of its authorized generic Adderall XR under the parties' License and Distribution Agreement that was signed in January 2006. [More]
Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Shire plc, today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US. [More]
NIDA's 2012 Monitoring the Future survey shows rates stable or down for most drugs

NIDA's 2012 Monitoring the Future survey shows rates stable or down for most drugs

Continued high use of marijuana by the nation's eighth, 10th and 12th graders combined with a drop in perceptions of its potential harms was revealed in this year's Monitoring the Future survey, an annual survey of eighth, 10th, and 12th-graders conducted by researchers at the University of Michigan. [More]